{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Budesonide", "query": { "intervention": "Oral Budesonide" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 54, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+Budesonide&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T22:18:36.886Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06076304", "title": "Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Sinus Infection", "Acute Sinusitis" ], "interventions": [ { "name": "amoxicillin/clavulanate potassium", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Budesonide nasal spray", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daniel Merenstein", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 3720, "start_date": "2023-11-21", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-09-16T22:18:36.886Z", "location_count": 7, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hyattsville", "state": "Maryland" }, { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06076304" }, { "nct_id": "NCT00679432", "title": "(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Blood sampling, endoscopy", "type": "PROCEDURE" }, { "name": "budesonide-MMX® 6 mg", "type": "DRUG" }, { "name": "budesonide-MMX® 9 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Asacol® 400 mg", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 510, "start_date": "2008-06", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2019-12-10", "last_synced_at": "2026-09-16T22:18:36.886Z", "location_count": 76, "location_summary": "Huntsville, Alabama • Mobile, Alabama • Sylacauga, Alabama + 67 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Sylacauga", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00679432" }, { "nct_id": "NCT02495168", "title": "Randomized, Placebo-Controlled, Multidose, Study Comparing Generic Budesonide/Formoterol Fumarate Dihydrate to Symbicort® in Asthmatic Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Generic Budesonide/Formoterol Fumarate Dihydrate", "type": "DRUG" }, { "name": "Symbicort® (Budesonide/Formoterol Fumarate Dihydrate)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 1714, "start_date": "2017-01-13", "completion_date": "2018-05-31", "has_results": true, "last_update_posted_date": "2019-11-29", "last_synced_at": "2026-09-16T22:18:36.886Z", "location_count": 17, "location_summary": "Surprise, Arizona • Huntington Beach, California • San Jose, California + 12 more", "locations": [ { "city": "Surprise", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "San Jose", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02495168" }, { "nct_id": "NCT00638456", "title": "Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Eosinophilic Esophagitis" ], "interventions": [ { "name": "Budesonide plus Prevacid", "type": "DRUG" }, { "name": "placebo plus Prevacid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ranjan Dohil", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 32, "start_date": "2008-02", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2019-08-14", "last_synced_at": "2026-09-16T22:18:36.886Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00638456" }, { "nct_id": "NCT02736409", "title": "An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis (EoE)" ], "interventions": [ { "name": "Oral Budesonide Suspension (OBS)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "11 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "11 Years to 55 Years" }, "enrollment_count": 219, "start_date": "2016-04-01", "completion_date": "2019-11-12", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-09-16T22:18:36.886Z", "location_count": 62, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "North Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02736409" }, { "nct_id": "NCT00728481", "title": "The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Eosinophilic Esophagitis", "Gastroesophageal Reflux Disease", "EE", "GERD" ], "interventions": [ { "name": "Esomeprazole", "type": "DRUG" }, { "name": "Budesonide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 51, "start_date": "2008-05", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2016-01-14", "last_synced_at": "2026-09-16T22:18:36.886Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00728481" }, { "nct_id": "NCT06067828", "title": "A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate", "type": "DRUG" }, { "name": "Treatment B: Budesonide and Formoterol Fumarate", "type": "DRUG" }, { "name": "Treatment C : Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 171, "start_date": "2023-10-24", "completion_date": "2026-01-22", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-09-16T22:18:36.886Z", "location_count": 7, "location_summary": "Los Angeles, California • Tarzana, California • Torrance, California + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Brooksville", "state": "Florida" }, { "city": "Anderson", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06067828" }, { "nct_id": "NCT05477108", "title": "Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Treatment A (BGF MDI HFO with oral activated charcoal)", "type": "DRUG" }, { "name": "Treatment B (BGF MDI HFA with oral activated charcoal)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 108, "start_date": "2022-07-29", "completion_date": "2023-04-11", "has_results": true, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-09-16T22:18:36.886Z", "location_count": 1, "location_summary": "Brooklyn, Maryland", "locations": [ { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05477108" }, { "nct_id": "NCT01532648", "title": "Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Budesonide MMX®", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "5-ASA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 510, "start_date": "2012-01-27", "completion_date": "2013-10-02", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-09-16T22:18:36.886Z", "location_count": 39, "location_summary": "Anaheim, California • Lakewood, California • San Diego, California + 36 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Lakewood", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Bristol", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01532648" }, { "nct_id": "NCT00393367", "title": "Budesonide Inhalation Suspension for Acute Asthma in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma", "Acute Asthma", "Reactive Airway Exacerbation" ], "interventions": [ { "name": "Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg", "type": "DRUG" }, { "name": "Prednisolone, prednisone, or methylprednisolone", "type": "DRUG" }, { "name": "Albuterol, ipratropium bromide", "type": "DRUG" }, { "name": "Ipratropium bromide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 179, "start_date": "2006-12", "completion_date": "2007-11", "has_results": true, "last_update_posted_date": "2012-08-10", "last_synced_at": "2026-09-16T22:18:36.886Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00393367" } ] }